GK's presentation to Ausbiotech Asia is now available at:...

GK's presentation to Ausbiotech Asia is now available at: https://www.noxopharm.com/site/PDF/1860_3/NoxopharmAusbiotechAsiaSeriesMarch2019Presentation

This is a shortened version of the already-published March corporate presentation, presumably because of time constraints, and focusses entirely on the DARRT program.

Notably, it states that the combination of Radiotherapy and Veyonda leads to stimulation of innate immune cells, leading to shrinkage of irradiated and non-irradiated lesions.  It looks like Noxopharm has identified the mechanism of action of Veyonda, when delivered by suppository; information which will be important when an IND application is considered by the FDA.

The next three months will be pivotal for Noxopharm, in my opinion, with 24-week data for DARRT-1 expected in May; and LuPIN data for the first 16 patients to be disclosed by St Vincent's at the SNMMI Annual Meeting in California in June.   

The market cap for Noxopharm is currently about $50 million, which coincidentally was the MC for Endocyte before it obtained the rights to LuPSMA - the radiopharmaceutical being used at St Vincent's in combination with Veyonda.  As we know, 18 months later the MC of Endocyte was about $1 billion; and the company was recently bought by Novartis for $2.1 billion, which was a 40-bagger in just two years or so.

Treatment with LuPSMA in Germany costs $15,000 per shot, which is reimbursed  I expect Novartis to charge at least $20,000 per shot, which means that a completed six-shot treatment cycle would cost $120,000.  If I remember correctly, one third of patients stop after one shot, and one third stop after three shots, which means that Novartis would miss out on potential earnings of about $72 million for every 1,000 patients!  If Veyonda improves the performance of LuPSMA, the MC of Noxopharm will not stay at $50m.